<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5109237 Figure_1-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Representative FACS plot (left) showing a mixed-lineage clone with a T-lymphoid (CD25+/CD11b-Gr1-), myeloid (CD11b+Gr1+/CD25-), and biphenotypic (CD11b+Gr1+/CD25+) fraction derived from a single Myc/Bcl2-transformed DN2cell grown on 1:1 OP9:OP9-Dll1 co-culture with lineage-promiscuous cytokines IL-2, IL-3, IL-6, IL-7, SCF,GM-CSF, Flt3. Morphology of the indicated flow-sorted cell fractions was analyzed by Giemsa staining (right).</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_1-B</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Phenotype frequencies of clones from Myc/Bcl2-transformed single cells (grown and phenotyped as mentioned in A). Analyzed were 31 clones from LSKs, 107 from GMPs and 28 from DN2 cells.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_1-C</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Cumulative survival of 31&#177;2 and 27&#177;6 days of mice that received 5104 to 5105 T-lymphoid cells or myeloid cells, respectively, that were flow-sorted from mixed Myc/Bcl2+ DN2-derived clones. The summarized data are from 3 mice injected with the T-lymphoid and 4 mice injected with the myeloid fraction of two different clones.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_1-D</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Representative FACS plots demonstrating predominant outgrowth of myeloid clones from single Myc/Bcl2-transformed LSK or GMPcells on OP9:OP9-Dll1 co-cultures.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_1-E</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. (top panels) Serial replating of Myc-Bcl2+DN2 cells in methylcellulose generated myeloid clones with stable genomic reassembly of the D&#946;1 TCR locus in vitro (gel: left two lanes). Upon transplantation, the same clones induced myeloid leukemia that retained the initial rearrangement in vivo (gel: right two lanes) as assessed by nested PCR. GL = germline. (bottom panels) Methylcellulose-based replating of Myc-Bcl2+GMPs generated myeloid clones that exclusively displayed the TCR&#223; locus in germline configuration.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_1-F</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 1-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Cumulative survival of mice that received 106cells of TCR&#946;-rearranged myeloid DN2-derived clones leading to death within 33&#177;4 days after transplantation. Two DN2 clones were transplanted into 5 recipient mice.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Representative FACS plots of spleens from leukemic recipient mice that had received LSK, GMP or DN2 cell grafts immediately after retroviral Myc/Bcl2 transduction. Numbers indicate frequencies (%) of CD45.2 donor cells within the indicated gates summarizing the mean&#177;SEM of at least 8 recipients per group from a total of 10 independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-B</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Cumulative survival of mice that received 2104 to 2105 freshly Myc/Bcl2-transduced LSK, GMP or DN2 cells; Graph shows n=11 Myc-Bcl2+ LSK-, n=14 DN2-, and n=8 GMP-transplanted animals.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-C</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Histological spleen sections of Myc-Bcl2+LSK-, GMP- or DN2-transplanted mice displaying myeloperoxidasestaining. Leukemic cell engraftment in spleens ranged from 75.1%-95.5%.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-D</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Multiplex quantitative RT-PCR demonstrating strong expression of PU.1 in the myeloid (M3L: CD11b+Gr1+/CD3-CD4-CD8-) and biphenotypic T/myeloid (BL: CD11b+Gr1+/CD3+CD4+CD8+) fractions but not in the T-lymphoid (TL: CD11b-Gr1-/CD3+CD4+CD8+) fraction that were flow-sorted from diseased Myc-Bcl2+DN2-transplanted mice. Myeloid progeny of Myc/Bcl2+GMP-transplanted or T-lymphoid progeny of Myc/Bcl2+DN3-transplanted animals as well as healthy thymocytes (Thy) and BM cells from WT mice served as controls. Results are shown as fold over actin transcripts.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-E</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. D-J rearrangement PCR of flow-sorted T-lymphoid (TL), biphenotypic (BL) and myeloid (ML) fractions of donor splenocytes of a diseased Myc/Bcl2+ DN2-transplanted mouse. All three fractions revealed a stable genomic reassembly of the D&#946;1 TCR locus (D&#946;1J&#946;1.5) demonstrating clonality in DN2 leukemia. thy = thymus.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-F</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-F</infon>
    <infon key="sourcedata_figure_dir">Figure_2-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. FACS plot of diseased intrathymic grafts (CD45.2-gated), demonstrating that Myc/Bcl2+ DN2 cells could produce multi-lineage leukemia within a T-cell supporting environment; Myc/Bcl2+ GMPs remained myeloid restricted under these conditions. Numbers indicate cell frequencies within the gates (mean&#177;SEM) representing six independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_2-G</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 2-G</infon>
    <infon key="sourcedata_figure_dir">Figure_2-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. Intrathymic transplantation of mock-infected non-leukemic DN2 cells produced predominantly T-lymphoid but also myeloid progeny 23 days after injection. This differentiation outcome resembles that of freshly isolated DN2 cells (Bell and Bhandoola, 2008; Richie Ehrlich et al., 2011), and indicates that the short-term culture necessary for retroviral transduction did not interfere with the physiological lineage potential of DN2 cells.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_3-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. GSEA demonstrates that Myc/Bcl2+ DN2-derived myeloid blasts were significantly (FDR &gt;0.05) enriched for expression of a pan-dendritic cell gene set. Gene sets were published in (Schonheit et al., 2013).</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_3-B</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Heat map of the top 100 differentially expressed genes (adjusted p-value of &#8804; 0.05) in each myeloid fraction (ML: CD11b+Gr1+/CD3-CD4-CD8-) from GMP-, LSK- and DN2-derived leukemias.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_3-D</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. GSEA demonstrates significant enrichment of a normal DN2-specific gene set (see methods section) in the Myc/Bcl2+ DN2-derived myeloid blasts.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_4-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Western blot illustrating abundant Bcl11b and Gata3protein expression in Myc/Bcl2+DN2- but not LSK- or GMP-derived blasts. Thymus (Thy) and bone marrow (BM) extracts from healthy WT mice served as controls. Detection of &#945;-tubulin or valosin-containing protein (VCP) ensured comparable loading.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_4-B-C</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 4-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>B,C. Proliferation assays illustrating growth of Myc/Bcl2+ DN2- (B) or GMP-derived (C) blasts after lentiviral transduction with the indicated shRNAs. The shRNA-transduced cells were flow-sorted based on co-expression of the RFP-reporter and seeded on OP9/OP9Dll1 1:1 layers. Growing cells were RFP-sorted for 3 rounds within 21 days of culture and percent growth was calculated over the initially seeded cell number in relation to the Luc control. Shown are results of 4 independent experiments with cells from 4 different DN2- and 3 different GMP-leukemic animals. Luc= control shRNA targeting luciferase (Suzuki et al., 2003). At least 2 different shRNAs were used against Bcl11b or Gata3 as indicated. * = p&#8804;0.05, Student's t-test.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_4-D</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 4-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Representative FACS plots showing CD45.2-donor splenocytes of a secondary (CD45.1) recipient 23 weeks after transplantation with 4103RFP+Myc-Bcl2+DN2-leukemia blasts carrying the indicated shRNAs. Luc: luciferase control shRNA. The data are representative of 2 Gata3, 4 Bcl11b, and 2 luciferase shRNA-transplanted animals.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_5-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Representative FACS plots of splenocytes from diseased secondary recipients that were transplanted with 104 to 105 flow-sorted myeloid leukemia blasts (ML: CD11b+Gr1+/CD3-CD4-CD8-) from sick primary Myc/Bcl2+LSK-, GMP- or DN2-transplanted mice. Cell percentages in indicated gates are shown.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_5-B</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Table summarizing the phenotype frequencies within the spleens of secondary recipients that were retransplanted with Myc/Bcl2+LSK-, GMP- or DN2-derived myeloid blasts as described in A. T-lymphoid leukemia: (TL: CD11b-Gr1-/CD3+CD4+CD8+), biphenotypic leukemia: BL (CD11b+Gr1+/CD3+CD4+CD8+), myeloid leukemia: ML (CD11b+Gr1+/CD3-CD4-CD8-). Numbers before the dash represent mice holding the indicated leukemia fraction; numbers after the dash indicate the total mouse count analyzed.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_5-C</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Single myeloid blasts from 4 different Myc/bcl2+ DN2-derived leukemias were flow-sorted from transplanted mice and grown on irradiated OP9:OP9DL1 stroma. The clones were analyzed at two different time points. FACS plots of two representative clones, one with strong (top) and one with weak (bottom) lineage switching potential are shown.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_5-D</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Table summarizing the lineage switching outcome of 20 independent clones that were grown from single DN2-derived myeloid blasts of 4 different leukemias. Percentages at the right indicate the relative amounts of cells with T-lymphoid (TL), biphenotypic (BL) or myeloid (ML) phenotype as analyzed by FACS at the end of the experiment.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_5-E</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 5-E</infon>
    <infon key="sourcedata_figure_dir">Figure_5-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. FACS plot of DN2-derived primary leukemic cells transduced with a retrovirus carrying GFP alone or GFP together with PU.1 as a bicistronic RNA. The transduced cells were grown on OP9/OP9Dll1 1:1 layer for 8-13 days and analyzed using a GFP-gate. The data are representative of 3 different experiments with similar outcome.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_6-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Heat map depicting all human AML samples from the Haferlach study (Haferlach et al., 2010) whose transcriptomes resembled DN2-leukemia by a Spearman's rank correlation coefficient &#8805; 0.5. The top 100 up- and downregulated gene signature of Myc/Bcl2+ DN2-derived myeloid blasts was applied (see also Figure 3B).</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_6-C-D-E</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 6-C-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>C,E. GSEA confirming enrichment of the Myc/Bcl2+DN2-derived myeloid blast top 100 UP (C) and pan-DC (Schonheit et al., 2013) (E) gene signatures in the human FAB M2 DN2-like AML samples as compared to all residual M2 AMLs from the Verhaak study (Verhaak et al., 2009). D. Relative transcript levels of the T cell receptor alpha locus (TRAC) in human DN2-like M2 AML compared to residual M2 AML patient samples from the Verhaak study (Wilcoxon rank-sum test, **=p&#8804;0.01).</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-A</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-A</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Survival assay of Myc/Bcl2+GMP- and DN2-derived leukemia cells that were isolated from diseased mice and treated for 24 h with 0.15 &#956;M daunorubicine or 1 &#956;M doxorubicine in liquid culture. Cell death was measured by FACS of 7-AAD+cells and was normalized to the solvent controls. The graphs show the mean+SEM of three different DN2- and five GMP-leukemias. **=p&#8804;0.01.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-C</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-C</infon>
    <infon key="sourcedata_figure_dir">Figure_7-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Scatterplot depicting the averaged quantitative changes (log10) of each shRNA within the library in the T1 spleen and BM samples in reference to T0. The changes in both organs were concordant (R2=0.72). T1 samples from 11 mice were compared to 3 T0 reference samples. Blue dots represent shRNAs with a significant depletion by &#8805;10-fold.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-D</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-D</infon>
    <infon key="sourcedata_figure_dir">Figure_7-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Top 5 genes with &#8805;10-fold shRNA depletion in BM, spleen and thymus in comparison to the reference.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-E</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Percent cell growth of 5 different DN2-derived leukemic cell lines transduced with 2 different shRNA constructs targeting Jak2. The cells were sorted for the GFP or YFP reporter and normalized to the control shRNA targeting the lacZ gene (lacZ). Four of five DN2-derived leukemias show reduced growth with both shRNAs after the second round of sorting within 8 days in culture. The lacZ control was set to 100%.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-F</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-F</infon>
    <infon key="sourcedata_figure_dir">Figure_7-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Proliferation curves of 3 Myc/Bcl2+ DN2- and 3 GMP-derived leukemia lines during treatment with 0.5 &#956;M ruxolitinib. 1.5105 cells were seeded in culture and counted at the indicated time points. Results are shown as fold growth of the starting cell number which was set to 1. *=p&#8804;0.05, **=p&#8804;0.01, Student's t-test.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-G</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-G</infon>
    <infon key="sourcedata_figure_dir">Figure_7-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. Western blot indicating active Jak/Stat signaling in DN2-derived leukemia with Stat3 as well as pStat3 protein expression, that diminishes after treatment with the Jak-inhibitor ruxolitinib.</text>
    </passage>
  </document>
  <document>
    <id>5109237 Figure_7-H</id>
    <infon key="sourcedata_document">2242</infon>
    <infon key="doi">10.15252/embj.201693927</infon>
    <infon key="pmc_id">5109237</infon>
    <infon key="figure">Figure 7-H</infon>
    <infon key="sourcedata_figure_dir">Figure_7-H</infon>
    <passage>
      <offset>0</offset>
      <text>H. GSEA indicating significant enrichment of genes of the JAK/STAT signaling pathway of the KEGG pathway database in the DN2-like M2 AML samples as compared to the residual M2 AML samples using the Verhaak AML data set (Verhaak et al., 2009).</text>
    </passage>
  </document>
</collection>
